Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Condition:   Neoplasms Intervention:   Drug: Letetresgene autoleucel Sponsor:   GlaxoSmithKline Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials